NGM Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	37.84	40.52	36.87	27.23	23.63	17.27	14.83
Research & Development	118.04	181.07	161.71	163.97	129.25	95.71	79.74
Operating Expenses	155.88	221.58	198.58	191.2	152.88	112.98	94.57
Operating Income	-155.88	-221.58	-198.58	-191.2	-152.88	-112.98	-94.57
Other Expense / Income	-13.51	-58.92	-78.24	-88.71	-110.09	-112.49	-79.35
Pretax Income	-142.38	-162.67	-120.34	-102.49	-42.8	-0.49	-15.22
Income Tax	0	0	0	0	0	0	-1.06
Net Income	-142.38	-162.67	-120.34	-102.49	-42.8	-0.49	-14.16
Shares Outstanding (Basic)	82	80	77	68	50	6	6
Shares Outstanding (Diluted)	82	80	77	68	50	6	6
Shares Change	3.18%	3.72%	12.57%	36.14%	687.90%	7.08%	-
EPS (Basic)	-1.73	-2.03	-1.56	-1.50	-0.85	-0.08	-2.37
EPS (Diluted)	-1.73	-2.03	-1.56	-1.50	-0.85	-0.08	-2.37
Free Cash Flow	-133.45	-146.3	-74.91	-85.38	-44.66	-13.44	-23.84
Free Cash Flow Per Share	-1.62	-1.83	-0.97	-1.25	-0.89	-2.11	-4.00
EBITDA	-138.06	-156.68	-112.44	-95.93	-35.19	6.73	-8.78
Depreciation & Amortization	4.32	5.98	7.9	6.56	7.61	7.22	6.44
EBIT	-142.38	-162.67	-120.34	-102.49	-42.8	-0.49	-15.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).